Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors
Hemispherian AS, a biotechnology company pioneering first-in-class TET2-activating therapeutics for difficult-to-treat cancers, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent application titled “Deoxy-Cytidine or Uridine Derivatives for Use in Cancer Therapies” (U.S. Patent Application No. 18/602,969).
